Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer

Expert Opinion on Biological Therapy

Volumn 8, Issue 12, 2008, Pages 1947-1953

  Tykodi, Scott S ^a,b,c   Thompson, John A ^a,b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

5T4 oncofetal antigen; Cancer vaccine; Cytotoxic T lymphocyte; Modified vaccinia ankara 5T4; TroVaxr

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CANCER VACCINE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IRINOTECAN; MVA 5T4; OXALIPLATIN; PLACEBO; SUNITINIB; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; HUMORAL IMMUNITY; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; KIDNEY CARCINOMA; LIVER METASTASIS; LOW DRUG DOSE; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PROSTATE CANCER; REVIEW;

ANTIBODY FORMATION; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS;

POXVIRIDAE;

EID: 57649242612     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802567298     Document Type: Review

References (42)

1. Papac RJ. Spontaneous regression of cancer. Cancer Treat Rev 1996;22:395-423
2. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4
3. Nagorsen D, Scheibenbogen C, Marincola FM, et al. Natural T cell immunity against cancer. Clin Cancer Res 2003;9:4296-303
4. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308
5. Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer 1988;57:239-46
6. Myers KA, Rahi-Saund V, Davison MD, et al. Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein. An antigen associated with metastasis contains leucine-rich repeats. J Biol Chem 1994;269:9319-24
7. Southall PJ, Boxer GM, Bagshawe KD, et al. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 1990;61:89-95
8. Griffiths RW, Gilham DE, Dangoor A, et al. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer 2005;93:670-7
9. Ali A, Langdon J, Stern P, Partridge M. The pattern of expression of the 5T4 oncofoetal antigen on normal, dysplastic and malignant oral mucosa. Oral Oncol 2001;37:57-64
10. Imamura F, Nagao H, Naritsuka H, et al. A leucine-rich repeat membrane protein, 5T4, is expressed by a subtype of granule cells with dendritic arbors in specific strata of the mouse olfactory bulb. J Comp Neurol 2006;495:754-68
11. Carsberg CJ, Myers KA, Stern PL. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int J Cancer 1996;68:84-92
12. Jones H, Roberts G, Hole N, et al. Investigation of expression of 5T4 antigen in cervical cancer. Br J Cancer 1990;61:96-100
13. Starzynska T, Rahi V, Stern PL. The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer 1992;66:867-9
14. Naganuma H, Kono K, Mori Y, et al. Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer. Anticancer Res 2002;22:1033-8
15. Starzynska T, Marsh PJ, Schofield PF, et al. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer 1994;69:899-902
16. Wrigley E, McGown AT, Rennison J, et al. 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer 1995;5:269-74
17. Mulder WM, Stern PL, Stukart MJ, et al. Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients. Clin Cancer Res 1997;3:1923-30
18. Starzynska T, Wiechowska-Kozlowska A, Marlicz K, et al. 5T4 oncofetal antigen in gastric carcinoma and its clinical significance. Eur J Gastroenterol Hepatol 1998;10:479-84
19. Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 2003;3:263-71
20. Harrop R, Ryan MG, Myers KA, et al. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer Immunol Immunother 2006;55:1081-90
21. Mulryan K, Ryan MG, Myers KA, et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol Cancer Ther 2002;1:1129-37
22. Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a Phase I/II trial. Clin Cancer Res 2006;12:3416-24
23. Dangoor A, Burt D, Harrop R, et al. A vaccinia-based vaccine (TroVax) targeting the oncofetal antigen 5T4 administered before and after surgical resection of colorectal cancer liver metastases: Phase II trial [abstract #2574]. J Clin Oncol 2006;24:(18 Suppl)
24. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 2007;13:4487-94
25. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother 2008;57:977-86
26. Cao A, Hernandez-McClain J, Willis JP, et al. Activity of MVA 5T4 alone or in combination with either interleukin-2 (IL-2) or interferon-a (IFN) in patients (Pts) with metastatic renal cell cancer (MRCC) [abstract #3069]. J Clin Oncol 2007;25:(18 Suppl)
27. Harrop R, Macdermott C, Shablak A, et al. Vaccination of renal cell cancer patients with TroVax (modified vaccinia Ankara delivering the tumor antigen 5T4) plus IFNa: A Phase II trial [abstract #3053]. J Clin Oncol 2008;26:(15 Suppl)
28. Hernandez-McClain J, Amato RJ, Shingler WH, et al. Vaccination of renal cell cancer (RCC) patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax[T]) administered + low dose interleukin-2 (IL-2): A Phase II trial [abstract #5101]. J Clin Oncol 2008;26:(15 Suppl)
29. Kaufman HL, Kim-Schulze S, Kim D, et al. Correlation of effector and regulatory T cell responses with clinical outcome in metastatic renal cell carcinoma patients treated with MVA-5T4 vaccine and high-dose interleukin-2 [abstract #3004]. J Clin Oncol 2008;26:(15 Suppl)
30. TroVax Renal Immunotherapy Survival Trial. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00397345 [Last Accessed 3 October 2008]
31. Oxford BioMedica Announces Data Safety Monitoring Board Recommendation For TroVax® Phase III TRIST Study. Available from: http://www.oxfordbiomedica.co.uk/news/2008-ob-21.asp [Last Accessed 3 October 2008]
32. Amato RJ, Drury N, Naylor S, et al. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother 2008;31:577-85
33. Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00521274 [Last Accessed 7 October 2008]
34. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15
35. Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 2006;12:3064-9
36. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007;13:3776-82
37. Letter to Investigators - 15 July 2008. Available from: http://www.trovax.co.uk/pdfs/investigators.pdf [Last Accessed October 6, 2008]
38. Products/TroVax®. Available from: http://www.oxfordbiomedica.co.uk/ Trovax.asp [Last Accessed October 6, 2008]
39. Redchenko I, Harrop R, Ryan MG, et al. Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. Immunology 2006;118:50-7
40. Shingler WH, Chikoti P, Kingaman SM, Harrop R. Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. Int Immunol 2008;20:1057-66
41. Griffiths RW, Elkord E, Gilham DE, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007;56:1743-53
42. Ling KL, Pratap SE, Bates GJ, et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 2007;7:7